Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins

Thrombosis and Haemostasis

Volumn 77, Issue 2, 1997, Pages 317-322

  Brieger, David ^a   Dawes, Joan ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b CRC for Biopharmaceutical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DRUG CARRIER; ENOXAPARIN; HEXADIMETHRINE BROMIDE; IODINE 125; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MANUFACTURE; FEMALE; ISOTOPE LABELING; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0031051446     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655961     Document Type: Article

References (27)

1. Dawes J, Pepper D. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-60.
2. Boneu B, Caranobe C, Sié P, Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-91.
3. Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. John Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore 1992.
4. Doutrempuich C, Guyot M, Lalanne M, Deharo E, Walenga J, Fareed J. Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects. Thromb Res 1989; 55: 419-26.
5. Brieger D, Dawes J. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane). Thromb Haemost 1994; 72: 275-80.
6. Lam L, Silbert J, Rosenberg R. The separation of active and inactive forms of heparin. Biochem Biophys Res Comm 1976; 69: 570-7.
7. Dawes J, Prowse C, Pepper D. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemost 1985; 54: 630-4.
8. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-23.
9. Andersson L, Barrowcliffe T, Holmer E, Johnson E, Sims G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-83.
10. Hodson B, Pepper D, Dawes J. Novel affinity chromatographic system for the single step purification of glycosaminoglycans from complex systems using volatile buffers. J Chromatog 1991; 565: 416-23.
11. Teien A, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410.
12. Fareed J, Walenga J, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989; 556: 333-53.
13. Østergaard P, Nilsson B, Bergquist D, Hedner U, Pedersen P. The effect of low molecular weight heparin on experimental thrombosis and haemostasis - the influence of production method. Thromb Res 1987; 45: 739-49.
14. Mardiguian J. French Patent No. 2482603, 1981.
15. Neilsen J, Østergaard P. Chemistry of heparin and low molecular weight heparin. Acta Chir Scand Suppl 1988; 543: 52-6.
16. Cifonelli J, King J. The distribution of 2-acetaminido-2-deoxy-D-glucose residues in mammalian heparins. Carb Res 1972; 21: 173-86.
17. Bara L, Billaud B, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-6.
18. Bratt G, Tornebohm E, Lockner D. Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-9.
19. Matzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerised heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101.
20. Lindahl A, Sandset P, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-49.
21. Bregengaard C, Nordfang O, Østergaard P, Petersen J, Meyn G, Diness V, Svendsen O, Hedner U. Pharmacokinetics of full length and two domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-7.
22. Larnkjœr A, Østergaard P, Flodgaard H. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb Res 1994; 75: 185-94.
23. van Rijn J, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-22.
24. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-35.
25. Sandset P, Abildgaard U, Larsen M. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 801-13.
26. Valentin S, Larnkjœr A, Østergaard P, Nielsen J, Nordfang O. Characterisation of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-83.
27. Warn-Cramer BJ, Maki SL, Rapaport SI. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits. Thromb Haemost 1993; 69: 221-6.